CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
Tovaxin Autologous T Cell Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00587691
NCT00587691Phase 2Completed
CompareCT.gov

An Open-Label, Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis

Opexa Therapeutics, Inc.·interventional·Posted Jan 7, 2008·Updated Jan 11, 2017

In Brief

A Phase 2 clinical trial evaluating Tovaxin Autologous T Cell Vaccine for Multiple Sclerosis, Relapsing-Remitting and Multiple Sclerosis, Secondary Progressive. Completed, enrolled 16 participants across 2 sites.

Detailed Summary

The purpose of the study is 1) to study the safety and tolerability of escalating doses of myelin peptide reactive T cells in MS patients and 2) to study the clinical effectiveness of T Cell Vaccine ion the clinical course of MS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 7, 2008
Enrollment StartJul 1, 2002
Primary CompletionJun 1, 2007
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 18.5 years ago

Interventions

Tovaxin Autologous T Cell Vaccinebiological

Primary Series (x1): 4 subcutaneous injections (wks 0, 4, 12 and 20 with 52 week evaluable period. Retreatment Series (x3): 3 subcutaneous injections (wks 0, 4, and 8) with 26-week evaluable periods. Retreatment Series (x3): 5 subcutaneous injections (wks 0, 8, 26, 24 and 32) with 52-week evaluable periods.